Mednax (MD) Earns Daily Coverage Optimism Rating of 0.10

Press coverage about Mednax (NYSE:MD) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mednax earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.9285415703298 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have effected Accern’s scoring:

Mednax (MD) opened at $50.59 on Wednesday. Mednax has a 1-year low of $40.56 and a 1-year high of $72.13. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. The company has a market cap of $4,750.19, a PE ratio of 15.51, a PEG ratio of 1.63 and a beta of 0.40.

Mednax (NYSE:MD) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter in the previous year, the firm posted $1.09 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. research analysts anticipate that Mednax will post 3.1 earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. Citigroup cut their target price on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Robert W. Baird upped their target price on shares of Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and set a $44.00 price objective on shares of Mednax in a research note on Friday, November 3rd. KeyCorp set a $51.00 target price on shares of Mednax and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets started coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the stock. Mednax presently has a consensus rating of “Hold” and a consensus price target of $54.50.

In related news, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Mednax (MD) Earns Daily Coverage Optimism Rating of 0.10” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with's FREE daily email newsletter.

Leave a Reply